EUROPEAN VACCINE INITIATIVE E.V

Their core work

The European Vaccine Initiative (EVI) is a Heidelberg-based non-profit that coordinates and accelerates vaccine research and development across Europe. They build and manage pan-European vaccine R&D infrastructure — from clinical trial networks to manufacturing quality standards — serving both human and veterinary vaccine development. EVI acts as a central coordination hub, connecting academic labs, clinical trial sites, and manufacturers to move vaccine candidates from research into clinical development. Their work spans the full vaccine pipeline: quality control standards, clinical trial acceleration, and increasingly, predictive modelling for vaccine impact on antimicrobial resistance.

What they specialise in

How they've shifted over time

EVI's early H2020 work (2016–2019) concentrated on foundational vaccine infrastructure: establishing R&D platforms covering human and veterinary vaccines, setting manufacturing and quality control standards (VAC2VAC), and building international cooperation with China (SENET). From 2020 onward, a clear shift occurred toward pandemic response, clinical trial network coordination (VACCELERATE), and data-driven approaches including AI, mathematical modelling, and controlled human infection models (Inno4Vac, PrIMAVeRa). The evolution shows a move from building infrastructure to actively deploying it for rapid vaccine development and emerging health threats.

EVI is moving from infrastructure builder to operational platform operator, increasingly integrating AI, modelling, and rapid-response capabilities — positioning itself as Europe's go-to coordinator for accelerated vaccine development.

How they like to work

EVI is a strong consortium leader, coordinating 6 of its 8 H2020 projects. With 129 unique partners across 28 countries, they function as a major networking hub rather than a narrow specialist. Their coordination-heavy profile means partnering with EVI typically means joining a large, well-structured consortium where EVI handles project management and cross-partner integration — ideal for organizations that want access to a broad European vaccine network without leading the administrative burden themselves.

EVI has built one of the broadest vaccine-sector networks in H2020, connecting 129 unique partners across 28 countries. Their reach spans well beyond the EU into international cooperation (notably China via SENET), making them a gateway to both European and global vaccine research communities.

What sets them apart

EVI occupies a rare niche as a dedicated, non-profit vaccine coordination organization — not a university lab, not a pharma company, but the connective tissue between them. Their ability to coordinate massive multi-country consortia (129 partners, 28 countries) while maintaining focus on practical outcomes like clinical trials and manufacturing standards makes them an unusually effective project lead. For anyone entering the European vaccine space, EVI is likely the single most connected entry point.

Highlights from their portfolio

• Inno4Vac
  Largest-funded project (EUR 1.7M to EVI) combining AI, controlled human infection models, and manufacturing innovation — represents EVI's future direction.
• VACCELERATE
  Built Europe's COVID-19 clinical trial accelerator platform, demonstrating EVI's ability to mobilize rapidly during a pandemic crisis.
• TRANSVAC2
  Core infrastructure project (EUR 1.3M) establishing the European Vaccine R&D Infrastructure covering the full pipeline from prophylactic to therapeutic, human to veterinary.